Meet Honorary Degree Recipient Angelos M. Stergiou, M.D. Doctor of Science (Sc.D.)

Dr. Angelos M. Stergiou is the founder, CEO and Chairman of SELLAS Life Sciences Group. He has held international positions of increasing responsibility in the United States and Europe with pharma and biotechnology companies and clinical research organizations over the past 14 years and, among others, he has founded and sold a boutique New York-based health economics and pricing-reimbursement and health access company.

StergiouDr. Stergiou holds a Doctor of Medicine degree and did elective clinical training in interventional cardiology and surgery at the University of Cologne in Germany.  He is a Fellow of the Royal Society of Medicine in the United Kingdom, a member of the World Medical Association, the American Academy of Physicians in Clinical Research, the American Association of Clinical Research Professionals, the International Society for Pharmacoeconomics and Outcomes Research and other organizations. He has published papers in peer-reviewed journals and has presented at prestigious conferences and post-secondary institutions, including Columbia University and numerous European universities on global biotechnology, clinical development and clinical research and regulatory matters.

He has served as a medical director, head of clinical research and vice president of product development, chief medical officer and chief operations officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, and manufacturing and controls.

Dr. Stergiou has led research endeavors in all phases of clinical development across many indications, including central nervous system, cardiovascular, oncology, respiratory and autoimmune diseases. He has designed and implemented research projects in many countries, and he has had numerous interactions with the U.S. Food and Drug Administration, Japanese Health Authority, Australian Health Authority, as well as the EMA (European Medical Agency).

He was a member of the senior management team responsible for placing one company on the German DAX and another on the NASDAQ and has successfully completed merger and acquisitions and license deals.  He led the development of a therapeutic cancer vaccine, for which he holds a patent, that is presently under review by health authorities.His current company, Sellas, is proceeding into pivotal Phase 3 studies with its WT1 cancer vaccine, licensed from Memorial Sloan Kettering Cancer Center, for acute myeloid leukemia and malignant pleural mesothelioma, as well as other indications across various phases of development, including ovarian cancer, glioblastoma multiforme, multiple myeloma and others.

He has collaborated with internationally renowned academic institutions on clinical research endeavors, including Beth Israel Deaconess Medical Center – Harvard University, M.D. Anderson Cancer Center, University of Pennsylvania, Cleveland Clinic, New York University, University of Heidelberg, Mayo Clinic, Memorial Sloan Kettering Cancer Center and more.